Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ultragenyx Pharmaceutical Inc. provides biotechnology services. The Company develops therapeutics and sialic acid for treating metabolic, body myopathy, glucuronidase, and rare genetic diseases. Ultragenyx Pharmaceutical conducts its business in the United States.
Website: ultragenyx.com



Growth: Good revenue growth rate 27.5%, there is acceleration compared to average historical growth rates 21.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -84.2%. On average the margin is improving steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.6 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 3.9% higher than minimum and 53.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.4x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.1 mln (-0.004% of cap.)

Key Financials (Download financials)

Ticker: RARE
Share price, USD:  (+0.1%)27.34
year average price 43.83  


year start price 44.86 2024-07-27

max close price 59.36 2024-09-16

min close price 26.31 2025-07-18

current price 27.34 2025-07-26
Common stocks: 70 152 192

Dividend Yield:  0.0%
EV / Sales: 2.3x
Margin (EBITDA LTM / Revenue): -84.2%
Fundamental value created in LTM:
Market Cap ($m): 1 918
Net Debt ($m): -563
EV (Enterprise Value): 1 355
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-22globenewswire.com

BROAD ARROW TO AUCTION DESIRABLE ASTON MARTIN ZAGATO DBZ CENTENARY COLLECTION IN MONTEREY

2025-07-18businesswire.com

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

2025-07-11globenewswire.com

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

2025-07-10proactiveinvestors.com

Ultragenyx shares plunge after bone disorder trial misses key interim goal

2025-06-30zacks.com

RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome

2025-06-24globenewswire.com

RARE FERRARI BERLINETTAS LINE UP FOR INAUGURAL BROAD ARROW ZOUTE CONCOURS AUCTION

2025-05-07zacks.com

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y

2025-05-06seekingalpha.com

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

2025-05-06zacks.com

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

2025-04-16seekingalpha.com

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-02 2024-05-03 2024-02-21 2023-11-03 2023-08-04 2023-05-05 2023-02-17 2022-11-03
acceptedDate 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 139M 147M 109M 127M 98M 108M 100M 103M 91M
costOfRevenue 21M 30M 26M 12M 11M 10M 12M 5M 9M
grossProfit 118M 117M 82M 115M 87M 98M 88M 98M 82M
grossProfitRatio 0.849 0.795 0.758 0.905 0.888 0.908 0.878 0.949 0.905
researchAndDevelopmentExpenses 170M 153M 170M 161M 157M 165M 166M 171M 237M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 80M 81M 78M 77M 75M 81M 77M 73M 70M
otherExpenses 0 -2M -2M 2M 5M -2M 7M 6M 0
operatingExpenses 250M 233M 248M 237M 232M 246M 242M 244M 307M
costAndExpenses 271M 263M 274M 249M 243M 256M 255M 249M 316M
interestIncome 11M 7M 9M 9M 6M 6M 6M 6M 3M
interestExpense 16M 16M 16M 17M 18M 15M 16M 16M 15M
depreciationAndAmortization 9M 9M 9M 43 812 5M 5M 7M 6M 2M
ebitda -109M -106M -157M -103M -140M -139M -148M -139M -223M
ebitdaratio -0.78 -0.731 -1.438 -0.81 -1.427 -1.28 -1.468 -1.347 -2.455
operatingIncome -132M -116M -165M -122M -145M -148M -154M -146M -225M
operatingIncomeRatio -0.946 -0.791 -1.519 -0.958 -1.48 -1.366 -1.533 -1.409 -2.481
totalOtherIncomeExpensesNet -1M -14M -5M -5M 4M -2M -9M -8M -14M
incomeBeforeTax -133M -131M -170M -127M -159M -159M -163M -153M -239M
incomeBeforeTaxRatio -0.955 -0.889 -1.564 -0.996 -1.622 -1.469 -1.627 -1.483 -2.633
incomeTaxExpense 303 000 858 000 455 000 -4M 650 000 732 000 495 000 -1M 6M
netIncome -134M -132M -171M -123M -160M -160M -164M -152M -245M
netIncomeRatio -0.957 -0.895 -1.568 -0.967 -1.628 -1.476 -1.632 -1.469 -2.702
eps -1.4 -1.52 -2.03 -1.52 -2.23 -2.25 -2.33 -2.16 -3.5
epsdiluted -1.4 -1.52 -2.03 -1.52 -2.23 -2.25 -2.33 -2.16 -3.5
weightedAverageShsOut 95M 87M 84M 81M 72M 71M 70M 70M 70M
weightedAverageShsOutDil 95M 87M 84M 81M 72M 71M 70M 70M 70M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-02 2024-05-03 2024-02-21 2023-11-03 2023-08-04 2023-05-05 2023-02-17 2022-11-03
acceptedDate 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 151M 487M 119M 214M 73M 102M 86M 133M 392M
shortTermInvestments 471M 283M 300M 364M 370M 450M 544M 615M 497M
cashAndShortTermInvestments 622M 770M 418M 777M 524M 552M 715M 897M 996M
netReceivables 93M 106M 100M 73M 79M 71M 43M 40M 31M
inventory 43M 40M 36M 34M 32M 28M 27M 27M 22M
otherCurrentAssets 41M 55M 41M -777M 46M 51M 67M 69M 71M
totalCurrentAssets 800M 965M 596M 732M 524M 702M 766M 884M 1 013M
propertyPlantEquipmentNet 272M 279M 285M 291M 323M 308M 301M 286M 263M
goodwill 44M 44M 44M 44M 44M 44M 44M 44M 44M
intangibleAssets 165M 166M 165M 166M 157M 158M 159M 160M 158M
goodwillAndIntangibleAssets 209M 211M 209M 211M 202M 203M 204M 205M 203M
longTermInvestments 203M 114M 160M 200M 4M 72M 90M 155M 121M
taxAssets 0 -1 0 6M 75M 0 0 0 0
otherNonCurrentAssets 54M 50M 56M 52M 110M 26M 22M 17M 18M
totalNonCurrentAssets 739M 654M 711M 759M 714M 609M 617M 662M 606M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 1 538M 1 618M 1 307M 1 491M 1 238M 1 311M 1 383M 1 545M 1 618M
accountPayables 36M 60M 41M 42M 33M 42M 59M 43M 24M
shortTermDebt 10M 59M 55M 13M 12M 11M 11M 12M 12M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 196M 0 168M 0 1M 3M
otherCurrentLiabilities 239M 154M 149M 29M 209M 24M 148M 205M 189M
totalCurrentLiabilities 285M 273M 246M 280M 254M 244M 218M 261M 227M
longTermDebt 24M 868M 849M 31M 35M 15M 17M 20M 23M
deferredRevenueNonCurrent 0 26M 28M 862M -35M 881M 0 0 0
deferredTaxLiabilitiesNonCurrent 30M 30M 30M 30M 32M 32M 32M 32M 33M
otherNonCurrentLiabilities 846M 15M 14M 12M 921M 10M 896M 880M 884M
totalNonCurrentLiabilities 900M 913M 921M 935M 952M 938M 945M 932M 922M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 24M 37M 28M 43M 12M 26M 29M 32M 35M
totalLiabilities 1 185M 1 186M 1 167M 1 216M 1 206M 1 182M 1 163M 1 193M 1 150M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 92 000 92 000 83 000 82 000 72 000 71 000 71 000 70 000 70 000
retainedEarnings -3 823M -3 690M -3 558M -3 388M -3 264M -3 105M -2 945M -2 781M -2 629M
accumulatedOtherComprehensiveIncomeLoss 896 000 2M 3M 647 000 -2M -3M -4M -7M -10M
othertotalStockholdersEquity 4 169M 4 120M 3 696M 3 662M 3 298M 3 237M 3 169M 3 140M 3 108M
totalStockholdersEquity 347M 432M 140M 275M 32M 129M 220M 352M 469M
totalEquity 354M 432M 140M 275M 32M 129M 220M 352M 469M
totalLiabilitiesAndStockholdersEquity 1 538M 1 618M 1 307M 1 491M 1 238M 1 311M 1 383M 1 545M 1 618M
minorityInterest 7M 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 538M 1 618M 1 307M 1 491M 1 238M 1 311M 1 383M 1 545M 1 618M
totalInvestments 674M 397M 460M 564M 374M 455M 549M 620M 618M
totalDebt 34M 927M 932M 43M 12M 26M 29M 32M 35M
netDebt -117M 440M 814M -170M -61M -76M -57M -101M -357M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-06 2024-08-02 2024-05-03 2024-02-21 2023-11-03 2023-08-04 2023-05-05 2023-02-17 2022-11-03
acceptedDate 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -134M -132M -171M -123M -160M -160M -164M -152M -245M
depreciationAndAmortization -28M 9M 9M 8M 7M 5M 5M 5M 5M
deferredIncomeTax 0 0 0 -139M -1M -3M 0 -2M 0
stockBasedCompensation 42M 39M 37M 34M 35M 35M 32M 29M 36M
changeInWorkingCapital 31M 16M -56M 13M 3M 7M -38M 22M 22M
accountsReceivables 10M 2M -25M 1M -6M -15M -3M -9M 6M
inventory -3M -4M -2M -2M -3M -2M 150 000 -4M -791 000
accountsPayables 11M 25M -36M 16M 7M 0 -34M 35M 11M
otherWorkingCapital 13M -7M 7M -2M 5M 24M -2M 122 000 6M
otherNonCashItems 22M 24M 107M 123M -2M -27 000 8M 7M 87M
netCashProvidedByOperatingActivities -67M -77M -191M -84M -118M -116M -157M -90M -95M
investmentsInPropertyPlantAndEquipment -2M -5M -13M -2M -4M -16M -25M -27M -26M
acquisitionsNet 0 0 0 3M 0 -3M 0 366 000 0
purchasesOfInvestments -367M -3M -22M -222M -139M -103M -62M -199M -211M
salesMaturitiesOfInvestments 94M 68M 132M 116M 208M 220M 202M 54M 151M
otherInvestingActivites -203 000 -41 000 -2M -271 000 -428 000 2M -4M -604 000 -76M
netCashUsedForInvestingActivites -276M 61M 94M -107M 64M 99M 111M -172M -162M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 117 000 385M -58 000 384M 25M 0 -750 000 11M 0
commonStockRepurchased 0 58 000 -58 000 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 11M 385M -58 000 331M 442 000 33M 28 000 -9M 492M
netCashUsedProvidedByFinancingActivities 11M 385M -58 000 331M 25M 33M -722 000 2M 492M
effectOfForexChangesOnCash 1M -648 000 -679 000 1M -716 000 -136 000 211 000 1M -1M
netChangeInCash -327M 368M -97M 145M -29M 16M -46M -259M 234M
cashAtEndOfPeriod 160M 487M 119M 219M 79M 108M 92M 138M 396M
cashAtBeginningOfPeriod 487M 119M 216M 75M 108M 92M 138M 396M 163M
operatingCashFlow -67M -77M -191M -84M -118M -116M -157M -90M -95M
capitalExpenditure -2M -5M -13M -2M -4M -16M -25M -27M -26M
freeCashFlow -69M -81M -204M -86M -122M -133M -182M -117M -121M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-02 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-07-29 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-05 21:01 ET
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
2024-10-29 20:05 ET
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
2024-10-07 12:00 ET
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
2024-10-03 20:30 ET
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
2024-09-26 12:00 ET
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
2024-09-18 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-08-21 20:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-08-02 12:15 ET
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP
2024-08-01 20:05 ET
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
2024-07-25 20:05 ET
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
2024-07-24 12:00 ET
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
2024-07-17 20:05 ET
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
2024-06-20 20:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-06-14 00:49 ET
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2024-06-12 20:05 ET
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2024-06-12 20:00 ET
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
2024-06-11 21:47 ET
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
2024-06-04 20:05 ET
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-30 20:00 ET
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
2024-05-17 20:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-05-07 20:30 ET
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
2024-05-02 20:00 ET
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
2024-04-30 20:00 ET
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
2024-04-30 12:00 ET
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
2024-04-25 20:30 ET
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
2024-04-19 20:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-04-15 11:00 ET
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
2024-04-12 20:22 ET
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
2024-04-12 12:00 ET
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
2024-03-22 20:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 21:30 ET
Ultragenyx to Participate at Investor Conferences in March
2024-02-23 21:05 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-02-15 21:01 ET
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2024-02-08 21:00 ET
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
2024-02-06 13:00 ET
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
2024-02-05 21:05 ET
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
2024-01-25 21:05 ET
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
2024-01-19 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-07 16:00 ET
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
2024-01-04 13:00 ET
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2024-01-04 13:00 ET
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2024-01-03 13:00 ET
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
2024-01-02 21:05 ET
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 21:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 13:00 ET
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2023-12-18 13:00 ET
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2023-11-20 21:30 ET
Ultragenyx to Participate at Investor Conferences in November
2023-11-17 21:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 22:00 ET
Ultragenyx to Participate in the Jefferies London Healthcare Conference
2023-11-02 20:05 ET
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
2023-10-26 20:05 ET
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
2023-10-23 20:01 ET
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2023-10-20 20:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-10-19 01:16 ET
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2023-10-17 20:02 ET
Ultragenyx Announces Proposed Public Offering of Common Stock
2023-10-16 12:00 ET
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
2023-10-14 20:30 ET
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
2023-10-12 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-10-09 12:00 ET
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
2023-10-05 12:00 ET
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
2023-09-25 21:13 ET
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
2023-09-20 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-08-31 13:00 ET
Ultragenyx to Participate at Investor Conferences in September
2023-08-18 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 20:00 ET
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
2023-07-31 12:00 ET
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
2023-07-27 21:00 ET
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
2023-07-18 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-07-12 12:00 ET
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
2023-07-06 12:00 ET
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
2023-06-21 12:00 ET
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
2023-06-20 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 21:00 ET
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-05 20:00 ET
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
2023-05-19 12:30 ET
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
2023-05-18 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-05-17 12:00 ET
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
2023-05-08 20:02 ET
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
2023-05-05 20:01 ET
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
2023-05-04 20:01 ET
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
2023-04-28 16:27 ET
Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors
2023-04-27 20:05 ET
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
2023-04-19 20:01 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-03-28 20:01 ET
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
2023-03-21 12:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-03-14 12:30 ET
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
2023-02-28 21:01 ET
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
2023-02-16 21:01 ET
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
2023-02-09 21:01 ET
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
2023-01-06 21:01 ET
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
2023-01-04 11:00 ET
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 21:01 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-11-22 21:01 ET
Ultragenyx to Present at Piper Sandler Healthcare Conference
2022-11-18 21:05 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-11-10 21:15 ET
Ultragenyx Announces Departure of Chief Financial Officer
2022-11-09 21:01 ET
Ultragenyx to Present at Upcoming Healthcare Conferences
2022-11-02 20:05 ET
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
2022-10-27 20:01 ET
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
2022-10-04 20:30 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-09-10 00:22 ET
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
2022-09-01 20:01 ET
Ultragenyx to Participate at Citi BioPharma Conference
2022-08-17 20:01 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-08-03 20:05 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-07-28 20:01 ET
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
2022-07-25 20:01 ET
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update
2022-07-20 21:09 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-07-18 20:00 ET
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study
2022-07-14 12:30 ET
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
2022-06-10 12:00 ET
Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
2022-06-01 20:01 ET
Ultragenyx to Present at Jefferies Global Healthcare Conference
2022-05-19 12:00 ET
Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
2022-05-09 12:00 ET
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
2022-05-05 20:05 ET
Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
2022-05-03 21:00 ET
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-05-03 20:05 ET
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
2022-04-27 20:01 ET
Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update
2022-04-25 17:18 ET
Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
2022-04-22 12:00 ET
Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
2022-04-20 12:00 ET
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

SEC forms

Show financial reports only

SEC form 10
2025-05-07 00:00 ET
Ultragenyx Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-06 20:10 ET
Ultragenyx Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-06 20:10 ET
Ultragenyx Pharmaceutical reported for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
Ultragenyx Pharmaceutical reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 10
2024-11-05 18:16 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 8
2024-11-05 16:06 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 8
2024-11-05 16:06 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 10
2024-08-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 10
2024-08-01 18:08 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 8
2024-08-01 16:07 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 8
2024-08-01 16:07 ET
Ultragenyx Pharmaceutical reported for 2024 q2
SEC form 10
2024-05-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 10
2024-05-02 18:05 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 8
2024-05-02 16:02 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 8
2024-05-02 16:02 ET
Ultragenyx Pharmaceutical reported for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ultragenyx Pharmaceutical reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 10
2023-11-02 18:15 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 8
2023-11-02 16:17 ET
Ultragenyx Pharmaceutical reported for 2023 q3
SEC form 8
2023-10-16 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 10
2023-08-03 18:03 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-08-03 16:08 ET
Ultragenyx Pharmaceutical reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-12 08:15 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-06 08:15 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-06-13 13:00 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-05 16:17 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Ultragenyx Pharmaceutical reported for 2023 q1
SEC form 6
2023-03-23 17:00 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-14 08:35 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 10
2023-02-17 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 10
2023-02-16 18:06 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 6
2023-02-16 16:08 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 6
2023-01-06 16:19 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 6
2022-11-10 16:26 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 10
2022-11-02 18:06 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 6
2022-10-28 16:10 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 6
2022-09-15 16:07 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 10
2022-07-29 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 10
2022-07-28 18:17 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 6
2022-07-28 16:09 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 6
2022-07-18 16:12 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-14 08:36 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 6
2022-06-27 16:12 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-17 08:06 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 10
2022-05-05 18:13 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 6
2022-05-05 16:01 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 6
2022-04-28 16:10 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-22 12:30 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-22 08:05 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 10
2022-02-15 16:19 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 10
2022-02-15 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-10 16:11 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-10 08:24 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-07 07:16 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 10
2021-11-02 18:20 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-02 16:14 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-07 08:18 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-09-27 08:16 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 10
2021-08-02 18:36 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-02 16:10 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 8
2021-08-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 6
2021-06-30 19:56 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-30 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-25 09:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-10 08:35 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-19 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-14 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-07 16:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-05-04 18:32 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-04 16:06 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-29 16:01 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-16 06:03 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-02-11 18:37 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-11 16:07 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-21 08:46 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-11 07:15 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-08 09:16 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2020-12-17 16:15 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-12-07 06:04 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-02 16:05 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 10
2020-10-27 16:20 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-27 16:07 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-26 16:11 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-23 08:16 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-13 17:52 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-13 06:07 ET
Ultragenyx Pharmaceutical published news for 2020 q3